Two Sigma Advisers
DMRA

Two Sigma Advisers’s Damora Therapeutics, Inc. Ordinary Shares DMRA Stock Holding History

Two Sigma Advisers’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,956
Closed -$123K – 2462
2023
Q2 		$123K Sell
1,956
-188
-9% -$10.2K ﹤0.01% 2186
2023
Q1 		$107K Sell
2,144
-360
-14% -$19K ﹤0.01% 2374
2022
Q4 		$72K Sell
2,504
-1,176
-32% -$48.8K ﹤0.01% 2330
2022
Q3 		$174K Sell
3,680
-516
-12% -$26.2K ﹤0.01% 2232
2022
Q2 		$181K Sell
4,196
-1,552
-27% -$71.2K ﹤0.01% 2300
2022
Q1 		$316K Sell
5,748
-5,608
-49% -$315K ﹤0.01% 2197
2021
Q4 		$860K Buy
11,356
+1,616
+17% +$127K ﹤0.01% 1636
2021
Q3 		$874K Buy
+9,740
New +$1.04M ﹤0.01% 1679

Other funds holding DMRA

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's DMRA Position: Q3 2023 in Review

Two Sigma Advisers sold out of Damora Therapeutics, Inc. Ordinary Shares (DMRA) in Q3 2023, closing a stake of 1,956 shares — an estimated $123K sold.

Two Sigma Advisers first reported a position in DMRA in Q3 2021 and held it in 8 quarters. The position peaked at $874K in Q3 2021. 21 funds tracked by Wall St. Rank hold DMRA as of Q3 2023.

  • Two Sigma Advisers reported no remaining Damora Therapeutics, Inc. Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 1,956 Damora Therapeutics, Inc. Ordinary Shares shares in Q3 2023, an estimated $123K.
  • Two Sigma Advisers first reported a position in Damora Therapeutics, Inc. Ordinary Shares in Q3 2021 and held it in 8 quarters.
  • Two Sigma Advisers's Damora Therapeutics, Inc. Ordinary Shares position peaked at $874K in Q3 2021.
  • 21 funds tracked by Wall St. Rank held Damora Therapeutics, Inc. Ordinary Shares as of Q3 2023.

Based on Two Sigma Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.